Perspective Therapeutics operates a theranostic business model, combining diagnostic imaging with targeted alpha-particle therapies (TATs) to treat various cancers. The company's lead clinical programs include VMT-α-NET for neuroendocrine tumors, VMT01 for metastatic melanoma, and PSV359 for solid tumors expressing fibroblast activation protein-alpha (FAP-α). By utilizing a chemically matched isotope pair (Pb-203 for imaging and Pb-212 for therapy), Perspective enables physicians to confirm tumor target expression prior to administering the therapeutic dose. The company is building a distributed manufacturing network, utilizing proprietary Pb-212 generators to supply its clinical trials. Perspective Therapeutics was formed in 2023 following the merger of Isoray, Inc. and Viewpoint Molecular Targeting, Inc., and subsequently sold its legacy Cesium-131 brachytherapy business in 2024 to focus exclusively on its radiopharmaceutical pipeline.
